Welcome to our dedicated page for Promis Neuroscie SEC filings (Ticker: PMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing can feel like reading a foreign language鈥攅specially when Promis Neurosciences (PMN) packs pages with clinical trial data, patent charts, and dilution risk tables. Whether you need the latest Promis Neurosciences quarterly earnings report 10-Q filing or want to confirm cash runway assumptions buried deep in the 10-K, Stock Titan鈥檚 AI has already highlighted the numbers that move the share price.
Our platform ingests every form鈥�10-K, 10-Q, 8-K, DEF 14A, S-1鈥攁nd produces plain-English explanations in minutes. Curious about Promis Neurosciences insider trading Form 4 transactions? We surface real-time alerts the moment executives report a trade, so you can track Promis Neurosciences executive stock transactions Form 4 without refreshing EDGAR all day. Need context on a sudden capital raise? The AI summary inside the 8-K pinpoints dilution impact and clinical milestone funding needs.
What investors learn here:
- Cash burn trends and R&D spend extracted from each 10-Q
- Phase 1/2 trial updates found in 8-K material events explained
- Board proposals and CEO compensation decoded from the proxy statement鈥攑erfect for anyone googling 鈥淧romis Neurosciences proxy statement executive compensation鈥�
- Historical Promis Neurosciences SEC filings explained simply with side-by-side comparisons
You鈥檒l still see every original document, but our AI-powered summaries, keyword search, and section-level redlining let you jump straight to the questions analysts ask on earnings calls: trial enrollment status, patent life, or dilution from at-the-market offerings. Stop scrolling through PDFs and start understanding Promis Neurosciences annual report 10-K simplified鈥攁ll in one place.
ProMIS Neurosciences filed a Form S-3 shelf registration to offer up to $50,000,000 of securities, including common shares, preferred shares, subscription receipts, debt, warrants and units. The filing expressly includes a sales agreement prospectus for up to $17,988,524 of common shares that may be sold under an at-the-market agreement with H.C. Wainwright & Co., LLC, and notes that any unsold portion of that $17,988,524 is available for other offerings under the $50,000,000 shelf.
ProMIS states its lead therapeutic, PMN310, is in a Phase 1b clinical trial and lists PMN267 and PMN442 as additional candidates. The company says net proceeds will generally be used to advance PMN310 and for working capital and corporate purposes. The prospectus confirms ProMIS common shares trade on Nasdaq under the symbol PMN and reports an August 11, 2025 closing price of $0.628.
The document discloses corporate facts including a 60:1 reverse share split in 2022 and that ProMIS is an emerging growth company and a smaller reporting company. It also highlights material risks disclosed in the prospectus, including liquidity/going-concern concerns and the potential illiquidity of certain securities that may not be listed.
ProMIS Neurosciences (PMN) reported a cash balance of $4,510,119 and total assets of $9,509,496 at June 30, 2025, with a shareholders' deficit of $(382,578). The company recorded a net loss of $10,117,029 for the three months and $17,464,932 for the six months ended June 30, 2025, producing negative operating cash flow of $8,781,048 for the six-month period. Quarterly operating expenses were $10,184,661, driven by $8,050,610 of PMN310 development costs this quarter and $12,776,951 year-to-date. Accrued liabilities rose to $7,043,908 from $480,962 at year-end. Management discloses substantial doubt about the company鈥檚 ability to continue as a going concern without additional financing. Subsequent events in July 2025 include aggregate gross proceeds described as $21.6 million from various warrant transactions, an RD offering of approximately $0.8 million, PIPE commitments of $2.4 million and $3.0 million, and acceptance of discounted warrant exercises for approximately $15.9 million. PMN310 is in a Phase 1b multiple ascending dose study; all Cohort 1 patients are enrolled and Cohort 2 enrollment is >50% complete, and the FDA granted Fast Track designation to PMN310 on July 21, 2025.
ProMIS Neurosciences Inc. filed a Form 8-K announcing it issued a press release reporting its financial condition and results for the three and six months ended June 30, 2025. The filing states the press release is available on the company's website under Investors/Financial Results and that a copy is furnished as Exhibit 99.1 to the report. The 8-K identifies the company as a Nasdaq-listed registrant trading as PMN on The Nasdaq Capital Market and indicates the registrant has the status of an emerging growth company.
The filing itself does not include the financial statements or numerical results; investors are directed to the press release (Exhibit 99.1) for the detailed financial figures and discussion of the companys performance for the reported periods.
Ally Bridge Group and affiliates have filed a passive Schedule 13G on ProMIS Neurosciences Inc. (PMN) covering an event date of 29 July 2025. Four related reporting persons鈥擜BG Management Ltd., Ally Bridge Group (NY) LLC, Ally Bridge MedAlpha Master Fund L.P. and Fan Yu鈥攋ointly report ownership.
- Shares owned: 6,058,738 common shares held of record by Ally Bridge MedAlpha Master Fund L.P.
- Ownership percentage: 11.8 % of the 51,511,310 shares outstanding (issuer-provided).
- Voting & dispositive power: Sole power 鈥� 0; shared power 鈥� 6,058,738 for both voting and disposition.
- Warrants: The Fund also holds 9,690,037 additional common shares issuable upon warrant exercise; these are excluded from the reported total because exercise is currently limited.
- Control structure: Fan Yu controls ABG Management Ltd., which is the sole member of Ally Bridge Group (NY) LLC, the manager of the Fund; each party disclaims beneficial ownership except as indirectly attributed.
- Filing type: Schedule 13G (Rule 13d-1[c]) denotes a passive investment with no intent to influence control.
The filing signals a sizeable healthcare-focused institutional stake but does not announce any transaction, operational change or intent to seek control of ProMIS.
On 31 Jul 2025 Shaf QIC LLC and its manager, Jonathan Shafmaster, filed Amendment No. 1 to Schedule 13G disclosing a 10.01 % beneficial stake in ProMIS Neurosciences Inc. (PMN).
Key details:
- Total securities reported: 10,534,639 Common Shares.
- Composition: 5,184,760 outstanding shares plus 5,349,879 shares underlying warrants.
- The warrants are subject to a 9.99 % ownership blocker, so fewer shares can currently be exercised; full ownership would reach 10.01 % of the 51,806,497 shares outstanding at 31 Jul 2025.
- All voting and dispositive power is solely held by the reporting persons; no shared power is indicated.
- The filing is made under Rule 13d-1(c) and includes a certification of passive intent鈥攏o present plans to influence control of the issuer.
The filing introduces a new >5 % shareholder and highlights potential dilution once the blocker constraint is lifted.
Form 4 filing for ProMIS Neurosciences (PMN) shows 10% owner Michael S. Gordon, via Title 19 Promis LLC, increasing his indirect stake.
- 25 Jul 2025: Exercised Tranches A鈥揅 warrants (119,800 shares each, total 359,400) at a reduced price of $0.83158 versus original $2.02/$2.50 strikes, lifting common-share holdings to 2,435,029.
- 29 Jul 2025: Purchased 539,100 new five-year warrants at a purchase price of $0.1875 per warrant; each is exercisable at $1.25 for one common share.
Gordon now holds 345,316 derivative securities plus the common shares noted. The actions signal insider commitment and supply up to 898,500 potential new shares, implying moderate dilution if all warrants are exercised.
FAQ
What is the current stock price of Promis Neuroscie (PMN)?
What is the market cap of Promis Neuroscie (PMN)?
